12:00 AM
 | 
Oct 15, 2015
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glycinamide ribonucleotide formyltransferase (GARFT); folate receptor 1 (FOLR1; FR-α); FOLR2 (FR-β); solute carrier family 46 folate transporter m

Cancer

INDICATION: Cancer

Mouse and cell studies identified an inhibitor of GARFT, FOLR1, FOLR2 and SLC46A1 that could help treat folate receptor-expressing cancers. Chemical synthesis and in vitro testing of pyrimidine antifolate thienoyl analogs identified...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >